Low-dose radiation before CAR-T therapy for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have large B-cell lymphoma that came back or did not respond after at least 2 prior treatments.
- You are eligible for standard CAR-T therapy with tisagenlecleucel (Tisa-cel).
- Your tumor tests positive for a marker called CD19.
- You have measurable disease and adequate organ function (heart, lungs, liver, kidneys, blood counts).
- You have not had CAR-T therapy, anti-CD19 therapy, or an allogeneic stem cell transplant before.
- You are willing to use effective birth control during treatment and for 12 months after, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial adds a low dose of radiation to the entire body before CAR T cell therapy for patients with acute lymphoblastic leukemia. The goal is to see if this extra step helps the CAR T cells work better, without adding much extra discomfort.
This trial tests whether giving a low dose of radiation to the whole body before receiving CAR T-cell therapy helps the treatment work better for people with certain types of lymphoma or multiple myeloma that have come back or not responded to earlier treatments.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.